Neuromyelitis Optica Spectrum Disorders
Also known as: Neuromyelitis Optica Spectrum Disorder / NMO Spectrum Disorder (NMOSD) / NMO Spectrum Disorder / NMOSD / Neuromyelitis optica [Devic] / Devic's disease / Neuromyelitis optica (disorder) / Neuromyelitis optica / Neuro-optic myelitis
Drug | Drug Name | Drug Description |
---|---|---|
DB01257 | Eculizumab | A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
DB12530 | Inebilizumab | A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). |
DB15762 | Satralizumab | A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB01257 | Eculizumab | Complement C5 | target |
DB12530 | Inebilizumab | B-lymphocyte antigen CD19 | target |
DB15762 | Satralizumab | Interleukin-6 receptor subunit alpha | target |